"Second 'H first, then A' deal of the year: InnoCare Biotech prepares for STAR Market after raising nearly 1.8 billion HKD in Hong Kong"
```
As A-share companies rush to the Hong Kong Stock Exchange, reverse operations are quietly emerging.
Recently, InnoCare Pharma (9606.HK) announced plans to list on the STAR Market.
This comes after Bio-Thera Solutions (2315.HK), the first "H first, then A" case this year, successfully obtained registration approval